Trillium Therapeutics Inc. added Helen Tayton-Martin to its board of directors.
Tayton-Martin is the chief business officer of Adaptimmune Therapeutics plc.
Discover more about S&P Global’s offerings
Trillium Therapeutics adds board member
Perspectivas América Latina 2023 Emerging Trends & Growth
Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in
A Cloud Migration Plan for Corporations featuring Snowflake®
Investor Activism Campaigns Hit Record High in 2022
Trillium Therapeutics Inc. added Helen Tayton-Martin to its board of directors.
Tayton-Martin is the chief business officer of Adaptimmune Therapeutics plc.